Literature DB >> 19539954

Estrogen treatment in multiple sclerosis.

Stefan M Gold1, Rhonda R Voskuhl.   

Abstract

Currently available treatments for multiple sclerosis (MS) reduce inflammatory lesions on MRI and decrease clinical relapses but have limited effects on disability. Novel treatment options that target both the inflammatory as well as the neurodegenerative component of the disease are therefore needed. A growing body of evidence from basic science and clinical studies supports the therapeutic potential of estrogens in MS. Mechanisms of action include both immunomodulatory and directly neuroprotective pathways. A first pilot trial of oral estriol treatment showed encouraging results. There are now several phase II trials underway to further determine the efficacy of estrogen treatment in MS.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19539954      PMCID： PMC2760629          DOI： 10.1016/j.jns.2009.05.028

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  84 in total

Review 1.  Neuroprotection by estradiol.

Authors:  L M Garcia-Segura; I Azcoitia; L L DonCarlos
Journal:  Prog Neurobiol       Date:  2001-01       Impact factor: 11.685

2.  Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory.

Authors:  C Leranth; R H Roth; J D Elsworth; F Naftolin; T L Horvath; D E Redmond
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

3.  MR imaging quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing.

Authors:  I Catalaa; J C Fulton; X Zhang; J K Udupa; D Kolson; M Grossman; L Wei; J C McGowan; M Polansky; R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  1999-10       Impact factor: 3.825

4.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

Authors:  Y Ge; R I Grossman; J K Udupa; L Wei; L J Mannon; M Polansky; D L Kolson
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

5.  Efficacy and safety of oral estriol for managing postmenopausal symptoms.

Authors:  K Takahashi; A Manabe; M Okada; H Kurioka; H Kanasaki; K Miyazaki
Journal:  Maturitas       Date:  2000-02-15       Impact factor: 4.342

6.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.

Authors:  R A Rudick; E Fisher; J C Lee; J Simon; L Jacobs
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

7.  Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women.

Authors:  T Hayashi; I Ito; H Kano; H Endo; A Iguchi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-04       Impact factor: 6.053

8.  Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women.

Authors:  H Itoi; H Minakami; R Iwasaki; I Sato
Journal:  Maturitas       Date:  2000-10-31       Impact factor: 4.342

9.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS.

Authors:  P A Brex; R Jenkins; N C Fox; W R Crum; J I O'Riordan; G T Plant; D H Miller
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501
View more
  31 in total

1.  Smoking: effects on multiple sclerosis susceptibility and disease progression.

Authors:  Dean M Wingerchuk
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

2.  Males still dominate animal studies.

Authors:  Irving Zucker; Annaliese K Beery
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

3.  Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons.

Authors:  Rory D Spence; Amy J Wisdom; Yuan Cao; Haley M Hill; Chandler R L Mongerson; Briana Stapornkul; Noriko Itoh; Michael V Sofroniew; Rhonda R Voskuhl
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

4.  An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.

Authors:  Kaoru Saijo; Jana G Collier; Andrew C Li; John A Katzenellenbogen; Christopher K Glass
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

Review 5.  Does dienogest influence the inflammatory response of endometriotic cells? A systematic review.

Authors:  Giovanni Grandi; Michael Mueller; Nick A Bersinger; Angelo Cagnacci; Annibale Volpe; Brett McKinnon
Journal:  Inflamm Res       Date:  2015-12-09       Impact factor: 4.575

6.  Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity.

Authors:  Tracey L Papenfuss; Nicole D Powell; Melanie A McClain; Ashley Bedarf; Amber Singh; Ingrid E Gienapp; Todd Shawler; Caroline C Whitacre
Journal:  J Immunol       Date:  2011-02-11       Impact factor: 5.422

7.  Sex-specific differences in retinal nerve fiber layer thinning after acute optic neuritis.

Authors:  Fiona Costello; William Hodge; Y Irene Pan; Jodie M Burton; Mark S Freedman; Peter K Stys; Jessie Trufyn; Randy Kardon
Journal:  Neurology       Date:  2012-10-17       Impact factor: 9.910

8.  Bringing CLARITY to gray matter atrophy.

Authors:  Rory D Spence; Florian Kurth; Noriko Itoh; Chandler R L Mongerson; Shannon H Wailes; Mavis S Peng; Allan J MacKenzie-Graham
Journal:  Neuroimage       Date:  2014-07-16       Impact factor: 6.556

9.  Icariin exerts estrogen-like activity in ameliorating EAE via mediating estrogen receptor β, modulating HPA function and glucocorticoid receptor expression.

Authors:  Zhisheng Wei; Mengxia Wang; Mingfan Hong; Shengpeng Diao; Aiqun Liu; Yeqing Huang; Qingyun Yu; Zhongxing Peng
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

10.  The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination.

Authors:  Rashad Hussain; Abdel M Ghoumari; Bartosz Bielecki; Jérôme Steibel; Nelly Boehm; Philippe Liere; Wendy B Macklin; Narender Kumar; René Habert; Sakina Mhaouty-Kodja; François Tronche; Regine Sitruk-Ware; Michael Schumacher; M Said Ghandour
Journal:  Brain       Date:  2013-01       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.